Our core focus lies in precision CAR-T monitoring and technical support for in vivo CAR development. After years of close cooperation with research, translational and early-stage clinical teams across the industry, we observe that advanced CAR design and delivery progress has made reliable detection & validation a key industry bottleneck.
At the conference, our team will showcase our technical advances covering four core fields:
• Anti-idiotype detection reagents covering CD19, BCMA, GPRC5D and CD20 (Leu16 scFv) targets
• Validated CD20 clones optimized for NHP research and in vivo CAR experimental workflows
• Targeting & construct development for CD3, CD5, CD7, CD8 and B-cell related CAR projects
• End-to-end technical solutions for in vivo CAR development, from vector delivery to sample monitoring
In collaboration with global partners, CytoArt develops integrated full-chain solutions for in vivo CAR-T programs spanning construct design, delivery validation and post-administration detection.
We welcome researchers developing in vivo CAR projects, NHP animal model studies, or teams encountering challenges with CAR-T detection reproducibility to visit our Booth #601 for technical discussion and cooperation consultation.
#ASGCT2026 #CART #CellTherapy #InVivoCAR #AntiIdiotypeAntibody